Cas:143543-81-1 N-[2-(4-methoxyphenyl)ethyl]-4,5-dihydro-1,3-thiazol-2-amine manufacturer & supplier

Chemical Name:N-[2-(4-methoxyphenyl)ethyl]-4,5-dihydro-1,3-thiazol-2-amine

CAS.NO:143543-81-1

Synonyms:N-[2-(4-methoxyphenyl)ethyl]-4,5-dihydro-1,3-thiazol-2-amine

Molecular Formula:C₁₂H₁₆N₂OS

Molecular Weight:236.33300

HS Code:2934100090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:389.3ºC at 760mmHg

Density:1.19g/cm3

Index of Refraction:1.6

PSA:58.92000

Exact Mass:236.09800

LogP:2.25890

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like N-[2-(4-methoxyphenyl)ethyl]-4,5-dihydro-1,3-thiazol-2-amine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,N-[2-(4-methoxyphenyl)ethyl]-4,5-dihydro-1,3-thiazol-2-amine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,N-[2-(4-methoxyphenyl)ethyl]-4,5-dihydro-1,3-thiazol-2-amine Use and application,N-[2-(4-methoxyphenyl)ethyl]-4,5-dihydro-1,3-thiazol-2-amine technical grade,usp/ep/jp grade.

Related News: However, pharmaceutical intermediates are subdivided into primary intermediates and advanced intermediates. Because primary intermediate suppliers can only provide simple intermediate production, they are at the front end of the industrial chain. The pressure of competition and price is the greatest. The price fluctuations of basic chemical raw materials have a greater impact on them. N-[2-(4-methoxyphenyl)ethyl]-4,5-dihydro-1,3-thiazol-2-amine manufacturer The entire set of results “strongly support” the Darzalex-Rd combo as a new standard of care for newly diagnosed, transplant-ineligible multiple myeloma patients, Thierry Facon, M.D., an investigator of the MAIA trial, said in a statement. N-[2-(4-methoxyphenyl)ethyl]-4,5-dihydro-1,3-thiazol-2-amine supplier If the results from that trial are positive, the company might apply to the U.S. Food and Drug Administration for the same accelerated approval pathway recently used to bring the controversial Alzheimer’s drug aducanumab to market, Novak said. N-[2-(4-methoxyphenyl)ethyl]-4,5-dihydro-1,3-thiazol-2-amine vendor In that group, the vaccine slowed brain decline by around 30% in two different clinical and functional tests, Novak said. N-[2-(4-methoxyphenyl)ethyl]-4,5-dihydro-1,3-thiazol-2-amine factory If the results from that trial are positive, the company might apply to the U.S. Food and Drug Administration for the same accelerated approval pathway recently used to bring the controversial Alzheimer’s drug aducanumab to market, Novak said.